Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder
- PMID: 23726511
- PMCID: PMC3810148
- DOI: 10.1016/j.biopsych.2013.04.013
Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder
Abstract
Background: Genetic factors influence the risk for posttraumatic stress disorder (PTSD), a potentially chronic and disabling psychiatric disorder that can arise after exposure to trauma. Candidate gene association studies have identified few genetic variants that contribute to PTSD risk.
Methods: We conducted genome-wide association analyses in 1578 European Americans (EAs), including 300 PTSD cases, and 2766 African Americans, including 444 PTSD cases, to find novel common risk alleles for PTSD. We used the Illumina Omni1-Quad microarray, which yielded approximately 870,000 single nucleotide polymorphisms (SNPs) suitable for analysis.
Results: In EAs, we observed that one SNP on chromosome 7p12, rs406001, exceeded genome-wide significance (p = 3.97 × 10(-8)). A SNP that maps to the first intron of the Tolloid-Like 1 gene (TLL1) showed the second strongest evidence of association, although no SNPs at this locus reached genome-wide significance. We then tested six SNPs in an independent sample of nearly 2000 EAs and successfully replicated the association findings for two SNPs in the first intron of TLL1, rs6812849 and rs7691872, with p values of 6.3 × 10(-6) and 2.3 × 10(-4), respectively. In the combined sample, rs6812849 had a p value of 3.1×10(-9). No significant signals were observed in the African American part of the sample. Genome-wide association study analyses restricted to trauma-exposed individuals yielded very similar results.
Conclusions: This study identified TLL1 as a new susceptibility gene for PTSD.
Keywords: American populations; TLL1; genome-wide association study; posttraumatic stress disorder.
© 2013 Published by Elsevier Inc on behalf of Society of Biological Psychiatry.
Conflict of interest statement
Dr. Kranzler has served as a consultant or advisory board member for Alkermes, Lilly, Lundbeck, Pfizer, and Roche. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which is supported by Lilly, Lundbeck, Abbott, and Pfizer. The other authors report no biomedical financial interests or potential conflicts of interest.
Figures


References
-
- Speed N, Engdahl B, Schwartz J, Eberly R. Posttraumatic stress disorder as a consequence of the POW experience. J Nerv Ment Dis. 1989;177:147–153. - PubMed
-
- Kulka RA, Schlenger WE, Fairbank JA. Trauma and the Vietnam War: Report of Findings from the National Vietnam Veterans Readjustment Study. New York: Brunner/Mazel; 1990.
-
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
-
- Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048–1060. - PubMed
-
- Bromet E, Sonnega A, Kessler RC. Risk factors for DSM-III-R posttraumatic stress disorder: Findings from the National Comorbidity Survey. Am J Epidemiol. 1998;147:353–361. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical